



AMENDMENT AFTER FINAL

U.S. Appln. No. 09/428,458

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-39. (Cancelled).

Claim 40. (Previously Presented) A pharmaceutical composition useful for treating humans comprising:

- (A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-monobutyryl-cAMPS and Rp-monobutyryl-cAMPS; and
- (B) a pharmaceutically acceptable adjuvant or filler.

Claims 41-44. (Cancelled).

Claim 45. (Currently Amended) A method for enhancing T cell proliferation in a subject afflicted with HIV or AIDS in need thereof, comprising administering to said subject a pharmaceutical composition comprising:

- (A) a pharmaceutically effective amount of a cAMP antagonist specific inhibitor of PKA RI_αC₂ isozyme, wherein said inhibitor is a cAMP antagonist and is a thio-substituted cAMP analog which is an equatorial diastereomer of 8-substituted 3',5' cyclic adenosine monophorothioate (Rp-8-substituted-cAMPS), and wherein said thio-substituted cAMP analog binds to an

AMENDMENT AFTER FINAL
U.S. Appln. No. 09/428,458

RI α subunit of said isozyme and acts as a selective or specific antagonist of said isozyme; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claims 46-47. (Cancelled).

Claim 48. (Previously Presented) The method of Claim 45, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS, Rp-piperidino-cAMPS, and Rp-8-Cl-cAMPS.

Claim 49. (Previously Presented) The method of Claim 48, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claims 50-51. (Cancelled).